The proportion of CD44+/CD24−/low after chemotherapy therapy was 9.5 times higher than that before chemotherapy in breast cancer, and breast CSCs served as an independent risk factor for predicting poor survival in breast cancer patients (Tanei et al., 2009). The gene discussed is CD44; the disease is breast cancer.